I’ve been writing a lot about the role of digital in pharmaceutical communications. If you don’t like that, you aren’t going to enjoy this posting. Sunday’s New York Times carried a highly interesting and large article called "Literacy Debate: Online, … Continue reading
Another action from the FDA today that gives a thumbs down to an investigational drug. Today Eisai announced that it had received a non-approvable letter for the investigational compound fospropofol disodium injection which has been in review at the FDA … Continue reading
This morning, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced receipt of a not approvable letter from the FDA for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia. It is noteworthy on a few fronts. First, it … Continue reading
In place of the Weekly Roundup this week, I am writing a regular post because of a new development I just saw on Twitter from my friend Brian Reid. So ok folks, first J&J got on board by creating their … Continue reading
I’ve decided to add a new category for Business/Industry News. In these cases, the posting will be a re-print of press releases affecting the industry that I find of high interest. This one is from Genentech on the Roche offer. … Continue reading
